Mark Neumann
CIK 1756211 · Chief Commercial Officer · last filed 2026-02-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
2
Total Filings
34
Lifetime Open-Market Net
-$20.59M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MANE | Chief Commercial Officer | — | $96.07 | — | $0 | 1 | 2026-02-05 |
| Intra-Cellular Therapies, Inc. (ITCI) Delisted | EVP, Chief Commercial Officer | 0 | $131.87 | $0 | -$20.59M | 33 | 2025-04-02 |
Recent Filings · Page 4 of 4
34 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-01-10 | Intra-Cellular Therapies, Inc. (ITCI) Delisted | Mixed | +14,790 | -$162.2K | EDGAR |
| 2019-10-17 | Intra-Cellular Therapies, Inc. (ITCI) Delisted | Mixed | +6,674 | -$55.9K | EDGAR |
| 2019-01-10 | Intra-Cellular Therapies, Inc. (ITCI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-10-17 | Intra-Cellular Therapies, Inc. (ITCI) Delisted | Grant (A) | — | $0 | EDGAR |
Showing 31–34 of 34
Prev
Page 4 of 4
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.